Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • A First-in-Human, Open Label, Phase I/II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patients with Advanced Tumors

    Cancer Categories
    • Head and Neck,Lung,Skin
    Karmanos Trial ID
    • 2020-019
    NCT ID
    • NCT04198818
    Age Group
    • Adult
    Scope
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase I
    Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
    • Phase I/II
    Principal Investigator

    Objective:

    Primary Objectives (Phase 1):

    1. To evaluate the safety and tolerability of HH2710 administered orally in patients with advanced tumors;
    2. To identify the Maximum Tolerated Dose (MTD) and/or Recommended Phase II dose (RP2D).

    Primary Objective (Phase 2): To evaluate efficacy of HH2710 in patients with advanced tumors with MAPK signaling pathway genetic alterations, at the recommended phase 2 dose (RP2D).

    Secondary Objective (Phase 1): To characterize the pharmacokinetic profile of HH2710 and selected metabolites when administered orally in patients with advanced tumors.

    Secondary Objectives (Phase 2):
    1. To evaluate the efficacy of HH2710 in advanced tumor patients with MAPK signaling pathway genetic alterations;
    2. To evaluate the safety of HH2710.

    Exploratory Objectives (Phase 1):
    1. To assess the preliminary efficacy of HH2710;
    2. To explore the changes of the pharmacodynamics (PD) markers of HH2710.

    Exploratory Objective (Phase 2): To explore the correlation of biomarkers with clinical outcomes.

  • Locations

    Locations

    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 800-527-6266

    Karmanos Cancer Institute at Lawrence and Idell Weisberg Cancer Treatment Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions
    Phone: 800-527-6266